Search research articles
Contact Us
Filters
Showing results (1-10 of 130) with videos related to
Page
of 13
Sort By:
Inflammatory Bowel Diseases
|
March 3, 2016
Biosimilars in Crohn's Disease and Ulcerative Colitis
Douglas C Wolf
Inflammatory Bowel Diseases
|
August 20, 2016
Reply
Douglas C Wolf
Inflammatory Bowel Diseases
|
August 12, 2003
Antibodies to "antibodies to tumor necrosis factor" and infusion reactions: is this infliximab's Achille's heel?
Douglas C Wolf
Toxicologic Pathology
|
January 7, 2003
Use of the spontaneous Tsc2 knockout (Eker) rat model of hereditary renal cell carcinoma for the study of renal carcinogens
Kevin S McDorman, Douglas C Wolf
Toxicology and Applied Pharmacology
|
January 26, 2005
Confounders in interpreting pathology for safety and risk assessment
Douglas C Wolf, Peter C Mann
Critical Reviews in Toxicology
|
November 3, 2016
Response to letter to the editor from Chappelle, Spence, and Tury concerning Wolf et al. 2016: Illustrative case using the RISK21 roadmap and matrix: prioritization for evaluation of chemicals found in drinking water. 2016, Crit. Rev. Toxicol. Vol 46: 43-53
Douglas C Wolf, Michelle R Embry
Mutation Research
|
May 4, 2004
The transcriptional profile of the kidney in Tsc2 heterozygous mutant Long Evans (Eker) rats compared to wild-type
Banalata Sen, Douglas C Wolf, Susan D Hester
The American Journal of Gastroenterology
|
June 10, 2020
Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate
Douglas C Wolf, Christine H Wolf, David T Rubin
Gastroenterology & Hepatology
|
January 25, 2013
Predicting Outcomes and Tailoring Therapy in the Diagnosis and Treatment of IBD
Ellen J Scherl, Ernest G Seidman, Douglas C Wolf
Critical Reviews in Toxicology
|
July 4, 2023
Is the 90-day dog study necessary for pesticide toxicity testing?
Patricia L Bishop, Vicki L Dellarco, Douglas C Wolf
Page
of 13
Search research articles
Search
Showing results (1-10 of 130) with videos related to
Sort By:
Page
of 13
Inflammatory Bowel Diseases
|
March 3, 2016
Biosimilars in Crohn's Disease and Ulcerative Colitis
Douglas C Wolf
Inflammatory Bowel Diseases
|
August 20, 2016
Reply
Douglas C Wolf
Inflammatory Bowel Diseases
|
August 12, 2003
Antibodies to "antibodies to tumor necrosis factor" and infusion reactions: is this infliximab's Achille's heel?
Douglas C Wolf
Toxicologic Pathology
|
January 7, 2003
Use of the spontaneous Tsc2 knockout (Eker) rat model of hereditary renal cell carcinoma for the study of renal carcinogens
Kevin S McDorman, Douglas C Wolf
Toxicology and Applied Pharmacology
|
January 26, 2005
Confounders in interpreting pathology for safety and risk assessment
Douglas C Wolf, Peter C Mann
Critical Reviews in Toxicology
|
November 3, 2016
Response to letter to the editor from Chappelle, Spence, and Tury concerning Wolf et al. 2016: Illustrative case using the RISK21 roadmap and matrix: prioritization for evaluation of chemicals found in drinking water. 2016, Crit. Rev. Toxicol. Vol 46: 43-53
Douglas C Wolf, Michelle R Embry
Mutation Research
|
May 4, 2004
The transcriptional profile of the kidney in Tsc2 heterozygous mutant Long Evans (Eker) rats compared to wild-type
Banalata Sen, Douglas C Wolf, Susan D Hester
The American Journal of Gastroenterology
|
June 10, 2020
Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate
Douglas C Wolf, Christine H Wolf, David T Rubin
Gastroenterology & Hepatology
|
January 25, 2013
Predicting Outcomes and Tailoring Therapy in the Diagnosis and Treatment of IBD
Ellen J Scherl, Ernest G Seidman, Douglas C Wolf
Critical Reviews in Toxicology
|
July 4, 2023
Is the 90-day dog study necessary for pesticide toxicity testing?
Patricia L Bishop, Vicki L Dellarco, Douglas C Wolf
Page
of 13